[{"id":"70578b33-80a9-42f4-9a13-82071422aadc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04528836","created_at":"2021-01-18T21:41:09.194Z","updated_at":"2024-07-02T16:35:13.988Z","phase":"Phase 1","brief_title":"First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04528836","lead_sponsor":"Navire Pharma Inc., a BridgeBio company","biomarkers":" EGFR • KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12","tags":["EGFR • KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMS-986466"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-03-19"},{"id":"d64a4376-f3c6-468c-8bab-9e4a850eabdc","acronym":"Argonaut","url":"https://clinicaltrials.gov/study/NCT05480865","created_at":"2022-07-29T15:55:28.505Z","updated_at":"2024-07-02T16:35:21.318Z","phase":"Phase 1","brief_title":"SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation","source_id_and_acronym":"NCT05480865 - Argonaut","lead_sponsor":"Navire Pharma Inc., a BridgeBio company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • BMS-986466"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-01"},{"id":"ee17af4b-a504-4d7f-9a7e-75d62a8f9ff6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05621525","created_at":"2022-11-18T14:59:17.769Z","updated_at":"2024-07-02T16:35:26.381Z","phase":"Phase 1","brief_title":"Phase I Study of the BBP-398 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05621525","lead_sponsor":"LianBio LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMS-986466"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/18/2022","start_date":" 10/18/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-13"}]